JP2005526850A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005526850A5 JP2005526850A5 JP2004505094A JP2004505094A JP2005526850A5 JP 2005526850 A5 JP2005526850 A5 JP 2005526850A5 JP 2004505094 A JP2004505094 A JP 2004505094A JP 2004505094 A JP2004505094 A JP 2004505094A JP 2005526850 A5 JP2005526850 A5 JP 2005526850A5
- Authority
- JP
- Japan
- Prior art keywords
- disease
- diabetic
- failure
- aliskiren
- amlodipine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- UXOWGYHJODZGMF-QORCZRPOSA-N Aliskiren Chemical compound COCCCOC1=CC(C[C@@H](C[C@H](N)[C@@H](O)C[C@@H](C(C)C)C(=O)NCC(C)(C)C(N)=O)C(C)C)=CC=C1OC UXOWGYHJODZGMF-QORCZRPOSA-N 0.000 claims description 10
- JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 claims description 10
- 229960004601 aliskiren Drugs 0.000 claims description 10
- HTIQEAQVCYTUBX-UHFFFAOYSA-N amlodipine Chemical compound CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl HTIQEAQVCYTUBX-UHFFFAOYSA-N 0.000 claims description 10
- 229960000528 amlodipine Drugs 0.000 claims description 10
- 201000010099 disease Diseases 0.000 claims 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 14
- 206010012601 diabetes mellitus Diseases 0.000 claims 12
- 206010019280 Heart failures Diseases 0.000 claims 9
- 229960002003 hydrochlorothiazide Drugs 0.000 claims 9
- 206010002383 Angina Pectoris Diseases 0.000 claims 6
- 206010020772 Hypertension Diseases 0.000 claims 6
- 208000001647 Renal Insufficiency Diseases 0.000 claims 6
- 201000006370 kidney failure Diseases 0.000 claims 6
- 230000002792 vascular Effects 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 201000001320 Atherosclerosis Diseases 0.000 claims 3
- 206010003658 Atrial Fibrillation Diseases 0.000 claims 3
- 206010003662 Atrial flutter Diseases 0.000 claims 3
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 3
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims 3
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 3
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 claims 3
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 claims 3
- 208000004248 Familial Primary Pulmonary Hypertension Diseases 0.000 claims 3
- 208000010412 Glaucoma Diseases 0.000 claims 3
- 206010018364 Glomerulonephritis Diseases 0.000 claims 3
- 206010019668 Hepatic fibrosis Diseases 0.000 claims 3
- 208000010159 IgA glomerulonephritis Diseases 0.000 claims 3
- 206010021263 IgA nephropathy Diseases 0.000 claims 3
- 206010049694 Left Ventricular Dysfunction Diseases 0.000 claims 3
- 208000019695 Migraine disease Diseases 0.000 claims 3
- 208000021642 Muscular disease Diseases 0.000 claims 3
- 201000009623 Myopathy Diseases 0.000 claims 3
- 208000018262 Peripheral vascular disease Diseases 0.000 claims 3
- 206010064911 Pulmonary arterial hypertension Diseases 0.000 claims 3
- 208000003782 Raynaud disease Diseases 0.000 claims 3
- 208000012322 Raynaud phenomenon Diseases 0.000 claims 3
- 206010039710 Scleroderma Diseases 0.000 claims 3
- 208000006011 Stroke Diseases 0.000 claims 3
- 206010042600 Supraventricular arrhythmias Diseases 0.000 claims 3
- 206010046798 Uterine leiomyoma Diseases 0.000 claims 3
- 206010047281 Ventricular arrhythmia Diseases 0.000 claims 3
- 238000009825 accumulation Methods 0.000 claims 3
- 239000004480 active ingredient Substances 0.000 claims 3
- 230000001154 acute effect Effects 0.000 claims 3
- 230000000747 cardiac effect Effects 0.000 claims 3
- 230000001684 chronic effect Effects 0.000 claims 3
- 230000001149 cognitive effect Effects 0.000 claims 3
- 208000033679 diabetic kidney disease Diseases 0.000 claims 3
- 210000002744 extracellular matrix Anatomy 0.000 claims 3
- 230000003176 fibrotic effect Effects 0.000 claims 3
- 206010061989 glomerulosclerosis Diseases 0.000 claims 3
- 206010020718 hyperplasia Diseases 0.000 claims 3
- 206010020871 hypertrophic cardiomyopathy Diseases 0.000 claims 3
- 208000017169 kidney disease Diseases 0.000 claims 3
- 201000010260 leiomyoma Diseases 0.000 claims 3
- 206010027599 migraine Diseases 0.000 claims 3
- 208000010125 myocardial infarction Diseases 0.000 claims 3
- 201000008312 primary pulmonary hypertension Diseases 0.000 claims 3
- 201000001474 proteinuria Diseases 0.000 claims 3
- 230000002685 pulmonary effect Effects 0.000 claims 3
- 208000005069 pulmonary fibrosis Diseases 0.000 claims 3
- 201000002793 renal fibrosis Diseases 0.000 claims 3
- 150000003839 salts Chemical group 0.000 claims 3
- 208000037812 secondary pulmonary hypertension Diseases 0.000 claims 3
- 208000024891 symptom Diseases 0.000 claims 3
- 206010039808 Secondary aldosteronism Diseases 0.000 claims 2
- 208000032594 Vascular Remodeling Diseases 0.000 claims 2
- 230000001627 detrimental effect Effects 0.000 claims 2
- 210000000329 smooth muscle myocyte Anatomy 0.000 claims 2
- PQSUYGKTWSAVDQ-UHFFFAOYSA-N Aldosterone Natural products C1CC2C3CCC(C(=O)CO)C3(C=O)CC(O)C2C2(C)C1=CC(=O)CC2 PQSUYGKTWSAVDQ-UHFFFAOYSA-N 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 230000002411 adverse Effects 0.000 claims 1
- 229960002478 aldosterone Drugs 0.000 claims 1
- PQSUYGKTWSAVDQ-ZVIOFETBSA-N aldosterone group Chemical group [C@@H]1(CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3[C@@H](O)C[C@]12C=O)C(=O)CO PQSUYGKTWSAVDQ-ZVIOFETBSA-N 0.000 claims 1
- 210000004204 blood vessel Anatomy 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 230000002062 proliferating effect Effects 0.000 claims 1
- 208000012201 sexual and gender identity disease Diseases 0.000 claims 1
- 208000015891 sexual disease Diseases 0.000 claims 1
- 210000002460 smooth muscle Anatomy 0.000 claims 1
- 206010005746 Blood pressure fluctuation Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US38154602P | 2002-05-17 | 2002-05-17 | |
| US60/381,546 | 2002-05-17 | ||
| PCT/EP2003/005188 WO2003097098A1 (en) | 2002-05-17 | 2003-05-16 | Pharmaceutical composition comprising a renin inhibitor, a calcium channel blocker and a diuretic |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010181380A Division JP2010280708A (ja) | 2002-05-17 | 2010-08-13 | レニンインヒビター、カルシウムチャネルブロッカーおよび利尿薬を含む医薬組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2005526850A JP2005526850A (ja) | 2005-09-08 |
| JP2005526850A5 true JP2005526850A5 (enExample) | 2010-04-22 |
| JP5288678B2 JP5288678B2 (ja) | 2013-09-11 |
Family
ID=29550141
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004505094A Expired - Fee Related JP5288678B2 (ja) | 2002-05-17 | 2003-05-16 | レニンインヒビター、カルシウムチャネルブロッカーおよび利尿薬を含む医薬組成物 |
| JP2010181380A Withdrawn JP2010280708A (ja) | 2002-05-17 | 2010-08-13 | レニンインヒビター、カルシウムチャネルブロッカーおよび利尿薬を含む医薬組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010181380A Withdrawn JP2010280708A (ja) | 2002-05-17 | 2010-08-13 | レニンインヒビター、カルシウムチャネルブロッカーおよび利尿薬を含む医薬組成物 |
Country Status (24)
| Country | Link |
|---|---|
| US (3) | US20050182042A1 (enExample) |
| EP (2) | EP1507558B8 (enExample) |
| JP (2) | JP5288678B2 (enExample) |
| KR (3) | KR20130109244A (enExample) |
| CN (1) | CN1655819A (enExample) |
| AT (1) | ATE520417T1 (enExample) |
| AU (1) | AU2003240669B2 (enExample) |
| BR (1) | BR0310084A (enExample) |
| CA (1) | CA2485081C (enExample) |
| CY (2) | CY1112013T1 (enExample) |
| DK (1) | DK1507558T3 (enExample) |
| EC (1) | ECSP045428A (enExample) |
| ES (1) | ES2369216T3 (enExample) |
| IL (1) | IL164837A (enExample) |
| LU (1) | LU92000I2 (enExample) |
| MX (1) | MXPA04011383A (enExample) |
| NO (1) | NO334382B1 (enExample) |
| NZ (1) | NZ536555A (enExample) |
| PL (1) | PL219032B1 (enExample) |
| PT (1) | PT1507558E (enExample) |
| RU (1) | RU2316318C2 (enExample) |
| SI (1) | SI1507558T1 (enExample) |
| WO (1) | WO2003097098A1 (enExample) |
| ZA (1) | ZA200408442B (enExample) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2165768B1 (es) | 1999-07-14 | 2003-04-01 | Almirall Prodesfarma Sa | Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen. |
| US8168616B1 (en) * | 2000-11-17 | 2012-05-01 | Novartis Ag | Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension |
| ES2369216T3 (es) * | 2002-05-17 | 2011-11-28 | Novartis Pharma Ag | Composición farmacéutica que comprende un inhibidor de renina, un bloqueador del canal de calcio y un diurético. |
| CN100444840C (zh) | 2003-05-15 | 2008-12-24 | 罗斯坎普研究有限公司 | 减少淀粉样沉积、淀粉样神经毒性和小胶质增生的药物 |
| WO2005077418A1 (en) * | 2004-02-17 | 2005-08-25 | Novartis Ag | Combination of renin inhibitor and diuretics |
| MY148773A (en) * | 2004-03-17 | 2013-05-31 | Novartis Ag | Galenic formulations of organic compounds |
| WO2005089731A2 (en) * | 2004-03-17 | 2005-09-29 | Novartis Ag | Use of renin inhibitors in therapy |
| ES2257152B1 (es) * | 2004-05-31 | 2007-07-01 | Laboratorios Almirall S.A. | Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos. |
| AU2005247105B2 (en) * | 2004-05-31 | 2010-11-11 | Laboratorios Almirall, S.A. | Combinations comprising antimuscarinic agents and corticosteroids |
| MY146830A (en) * | 2005-02-11 | 2012-09-28 | Novartis Ag | Combination of organic compounds |
| AU2006227283B2 (en) * | 2005-03-22 | 2010-07-01 | Novartis Ag | Biomarkers for efficacy of aliskiren as a hypertensive agent |
| WO2007056324A2 (en) * | 2005-11-08 | 2007-05-18 | Novartis Ag | Combination of an angiotensin ii receptor blocker, a calcium channel blocker and another active agent |
| AR057882A1 (es) | 2005-11-09 | 2007-12-26 | Novartis Ag | Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra |
| GB0612540D0 (en) * | 2006-06-23 | 2006-08-02 | Novartis Ag | Galenical formulations of organic compounds |
| EP1891937A1 (en) * | 2006-08-25 | 2008-02-27 | Novartis AG | Galenic formulations of aliskiren |
| CA2668828A1 (en) * | 2006-11-07 | 2008-05-29 | Novartis Ag | Crystalline forms of aliskiren hemifumarate |
| RU2456267C2 (ru) * | 2006-11-09 | 2012-07-20 | Новартис Аг | Соль алискирена и оротовой кислоты |
| US8247370B2 (en) * | 2006-12-04 | 2012-08-21 | Promedior, Inc. | Conjoint therapy for treating fibrotic diseases |
| JP2010518147A (ja) * | 2007-02-16 | 2010-05-27 | ノバルティス アーゲー | 有機化合物の使用 |
| EP1972335A1 (en) * | 2007-03-23 | 2008-09-24 | Krka | Solid dosage forms comprising aliskiren and pharmaceutically acceptable salts thereof |
| RU2363472C2 (ru) * | 2007-05-22 | 2009-08-10 | Государственное образовательное учреждение высшего профессионального образования "Санкт-Петербургский государственный медицинский университет имени академика И.П. Павлова Федерального агентства по здравоохранению и социальному развитию" | Способ профилактики и лечения кардиоваскулярных осложнений у больных с хронической болезнью почек, находящихся на гемодиализе, имеющих анурию |
| US8497243B2 (en) * | 2007-07-06 | 2013-07-30 | Promedior, Inc. | Methods and compositions useful in the treatment of mucositis |
| US9884899B2 (en) | 2007-07-06 | 2018-02-06 | Promedior, Inc. | Methods for treating fibrosis using CRP antagonists |
| BRPI0817516A2 (pt) | 2007-10-05 | 2015-06-16 | Alzheimer S Inst Of America Inc | Método para reduzir deposição de amilóide, neurotoxicidade de amilóide e microgliose com o enantiômero de (-)-nilvadipino |
| EP2062874B1 (en) | 2007-11-20 | 2014-12-17 | KRKA, tovarna zdravil, d.d., Novo mesto | Process and intermediates for the preparation of aliskiren |
| EP2100599A1 (en) | 2008-03-13 | 2009-09-16 | Laboratorios Almirall, S.A. | Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease |
| RU2372079C1 (ru) * | 2008-05-20 | 2009-11-10 | Илья Николаевич Медведев | Способ коррекции уровня микровезикул в крови при артериальной гипертонии, дислипидемии и нарушении толерантности к глюкозе |
| RU2373932C1 (ru) * | 2008-05-20 | 2009-11-27 | Илья Николаевич Медведев | Способ коррекции уровня микровезикул в крови при артериальной гипертонии |
| JO3239B1 (ar) * | 2008-09-22 | 2018-03-08 | Novartis Ag | تركيبات جالينية من مركبات عضوية |
| RU2382644C1 (ru) * | 2008-11-05 | 2010-02-27 | Государственное образовательное учреждение высшего профессионального образования "Пермская государственная медицинская академия имени академика Е.А. Вагнера Федерального агентства по здравоохранению и социальному развитию" | Способ коррекции гипертрофии левого желудочка у больных ибс в сочетании с гипертонической болезнью |
| SI2189442T1 (sl) | 2008-11-20 | 2015-03-31 | Krka, Tovarna Zdravil, D.D., Novo Mesto | Postopek in intermediati za pripravo aliskirena |
| CA2755047C (en) * | 2009-03-11 | 2018-12-04 | Promedior, Inc. | Treatment methods for autoimmune disorders |
| PT2405928T (pt) * | 2009-03-11 | 2017-02-07 | Promedior Inc | Métodos de tratamento e de diagnóstico para patologias de hipersensibilidade |
| UA110323C2 (en) * | 2009-06-04 | 2015-12-25 | Promedior Inc | Derivative of serum amyloid p and their receipt and application |
| AU2010262847B2 (en) * | 2009-06-17 | 2016-06-02 | Promedior, Inc. | SAP variants and their use |
| EP2510928A1 (en) | 2011-04-15 | 2012-10-17 | Almirall, S.A. | Aclidinium for use in improving the quality of sleep in respiratory patients |
| CN102247344A (zh) * | 2011-05-30 | 2011-11-23 | 北京阜康仁生物制药科技有限公司 | 一种新型降血压组合物 |
| CN102552277A (zh) * | 2011-12-02 | 2012-07-11 | 邬林祥 | 氨氯地平、阿利可仑和氢氯噻嗪复方降压药物 |
| CN102626391B (zh) * | 2012-04-19 | 2013-07-10 | 海南美兰史克制药有限公司 | 一种阿利克仑氢氯噻嗪药物组合物脂质体固体制剂 |
| GB201317373D0 (en) | 2013-10-01 | 2013-11-13 | Univ Dundee | Treatment and prevention of cancer |
| CN111789843A (zh) * | 2019-04-08 | 2020-10-20 | 深圳奥萨医药有限公司 | 含氨氯地平、氯噻酮和阿米洛利的药物组合物 |
| KR102414285B1 (ko) * | 2020-06-02 | 2022-06-28 | 이화여자대학교 산학협력단 | 플루나리진 또는 이의 약학적으로 허용 가능한 염을 유효성분으로 함유하는 골질환의 예방 또는 치료용 약학적 조성물 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5350771A (en) * | 1989-03-22 | 1994-09-27 | Peter K. T. Pang | Method and treatment for hypertension using combination therapy involving exogenous calcium and calcium channel blockers |
| US5656650A (en) * | 1990-12-14 | 1997-08-12 | Smithkline Beecham Corp. | Angiotensin II receptor blocking compositions |
| JP3398379B2 (ja) * | 1990-12-14 | 2003-04-21 | スミスクライン・ビーチャム・コーポレイション | アンジオテンシンｉｉ受容体遮断組成物 |
| US5178877A (en) * | 1991-01-04 | 1993-01-12 | Abbott Laboratories | Encapsulated renin inhibitor composition |
| US5114925A (en) * | 1991-01-22 | 1992-05-19 | Merck & Co., Inc. | Renin inhibitors containing the 2-[[(2R,3S)-3-amino-4-cyclohexyl-2-hydroxy-1-butyl]thio)alkanoyl moiety and the corresponding sulfoxide and sulfone derivatives |
| US5256667A (en) * | 1991-09-25 | 1993-10-26 | Merck & Co., Inc. | Quinazolinones and pyridopyrimidinones |
| US5202322A (en) * | 1991-09-25 | 1993-04-13 | Merck & Co., Inc. | Quinazolinone and pyridopyrimidine a-II antagonists |
| US5292741A (en) * | 1992-08-18 | 1994-03-08 | Merck & Co., Inc. | Macrocycles incorporating quinazolinones |
| MY119161A (en) | 1994-04-18 | 2005-04-30 | Novartis Ag | Delta-amino-gamma-hydroxy-omega-aryl-alkanoic acid amides with enzyme especially renin inhibiting activities |
| EP0795327A1 (en) * | 1996-03-13 | 1997-09-17 | Pfizer Inc. | Use of Amlodipine for the treatment and prophylaxis of congestive cardiac failure of non-ischaemic origin |
| US8168616B1 (en) * | 2000-11-17 | 2012-05-01 | Novartis Ag | Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension |
| CA2430924A1 (en) * | 2000-12-01 | 2002-06-06 | Novartis Ag | Angiotensin receptor antagonist composition for the treatment of sexual dysfunction associated with hypertension and another condition |
| EP1426051B1 (en) * | 2001-09-11 | 2008-07-16 | Asahi Kasei Pharma Corporation | Medicinal composition for prevention of or treatment for cerebrovascular disorder |
| US7019010B2 (en) * | 2001-09-27 | 2006-03-28 | Novertis Ag | Combinations |
| ES2369216T3 (es) * | 2002-05-17 | 2011-11-28 | Novartis Pharma Ag | Composición farmacéutica que comprende un inhibidor de renina, un bloqueador del canal de calcio y un diurético. |
-
2003
- 2003-05-16 ES ES03730064T patent/ES2369216T3/es not_active Expired - Lifetime
- 2003-05-16 AT AT03730064T patent/ATE520417T1/de active
- 2003-05-16 CN CNA03811237XA patent/CN1655819A/zh active Pending
- 2003-05-16 NZ NZ536555A patent/NZ536555A/en not_active IP Right Cessation
- 2003-05-16 SI SI200332071T patent/SI1507558T1/sl unknown
- 2003-05-16 DK DK03730064.7T patent/DK1507558T3/da active
- 2003-05-16 JP JP2004505094A patent/JP5288678B2/ja not_active Expired - Fee Related
- 2003-05-16 CA CA2485081A patent/CA2485081C/en not_active Expired - Fee Related
- 2003-05-16 AU AU2003240669A patent/AU2003240669B2/en not_active Ceased
- 2003-05-16 WO PCT/EP2003/005188 patent/WO2003097098A1/en not_active Ceased
- 2003-05-16 EP EP03730064A patent/EP1507558B8/en not_active Expired - Lifetime
- 2003-05-16 RU RU2004137104/15A patent/RU2316318C2/ru not_active IP Right Cessation
- 2003-05-16 BR BR0310084-7A patent/BR0310084A/pt not_active Application Discontinuation
- 2003-05-16 KR KR1020137023159A patent/KR20130109244A/ko not_active Ceased
- 2003-05-16 PL PL372203A patent/PL219032B1/pl unknown
- 2003-05-16 PT PT03730064T patent/PT1507558E/pt unknown
- 2003-05-16 EP EP10177741A patent/EP2316488A1/en not_active Withdrawn
- 2003-05-16 US US10/514,683 patent/US20050182042A1/en not_active Abandoned
- 2003-05-16 MX MXPA04011383A patent/MXPA04011383A/es active IP Right Grant
- 2003-05-16 KR KR1020107028689A patent/KR20100137026A/ko not_active Ceased
- 2003-05-16 KR KR10-2004-7018479A patent/KR20050008717A/ko not_active Ceased
-
2004
- 2004-10-19 ZA ZA200408442A patent/ZA200408442B/en unknown
- 2004-10-25 IL IL164837A patent/IL164837A/en not_active IP Right Cessation
- 2004-11-12 EC EC2004005428A patent/ECSP045428A/es unknown
- 2004-12-15 NO NO20045459A patent/NO334382B1/no not_active IP Right Cessation
-
2008
- 2008-08-08 US US12/188,604 patent/US8183295B2/en not_active Expired - Fee Related
-
2010
- 2010-08-13 JP JP2010181380A patent/JP2010280708A/ja not_active Withdrawn
-
2011
- 2011-11-07 CY CY20111101071T patent/CY1112013T1/el unknown
- 2011-11-30 US US13/307,567 patent/US20120071470A1/en not_active Abandoned
-
2012
- 2012-05-14 CY CY2012011C patent/CY2012011I1/el unknown
- 2012-05-14 LU LU92000C patent/LU92000I2/fr unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005526850A5 (enExample) | ||
| KR20100137026A (ko) | 레닌 억제제, 칼슘 채널 차단제 및 이뇨제를 포함하는 약제학적 조성물 | |
| US20080027032A1 (en) | Combinations comprising cox-2 inhibitors and aspirin | |
| JP2010280708A5 (enExample) | ||
| US20110166220A1 (en) | Dronedarone for the prevention of permanent atrial fibrillation | |
| JP2011518785A (ja) | 心血管入院または死亡の予防に用いる薬剤を調製するためのドロネダロンの使用 | |
| EP3027183B1 (en) | Selective at2 receptor agonists for use in treatment of cachexia | |
| AU2019397511B2 (en) | Sulcardine administration for treatment of acute atrial fibrillation | |
| CN102869357A (zh) | 舒欣啶及其盐的缓慢滴注 | |
| CA2739463C (en) | Methods and compositions for treatment of acute heart failure | |
| CA3154859A1 (en) | Use of a ppar-delta agonist in the treatment of kidney disease | |
| KR20110026421A (ko) | 심장율동전환의 예방을 위한 드로네다론 | |
| CN102470138A (zh) | 钠-质子交换蛋白抑制剂和二氢-1,3,5-三嗪胺衍生物的组合产品 | |
| JP2011517694A (ja) | ドロネダロンと少なくとも１つの利尿薬の組み合わせおよびこの治療的使用 | |
| AU8081598A (en) | Method for treating heart failure | |
| Rabbani et al. | The role of magnesium therapy in acute myocardial infarction | |
| WO2003094924A1 (en) | Combination therapy for treating cyclooxygenase-2 mediated diseases in patients at risk of thrombotic cardiovascular events | |
| CN106390126A (zh) | 含有沙坦类药物和NEPi的药物组合物 | |
| JP2012522024A (ja) | 左旋性アムロジピン複合薬組成物 | |
| JP2006520343A (ja) | ２−（ブチル−１−スルホニルアミノ）−ｎ−［１（ｒ）−（６−メトキシピリジン−３−イル）プロピル］ベンズアミド、医薬としてのその使用及び該化合物を含有する医薬製剤 | |
| JP5982715B2 (ja) | 抗高血圧薬組成物 | |
| US20180311241A1 (en) | Pharmaceutical synergistic combination | |
| JP2005519072A (ja) | 心不全、他の加齢関連臓器機能不全および加齢関連障害の予防のための、ならびに寿命を延長するための、ナトリウム−水素交換阻害剤であるカリポライドとａｃｅ阻害剤との組み合わせ製剤 | |
| HK1249437B (en) | Aica riboside analogs for treatment of acute decompensated heart failure | |
| EP3445342A1 (fr) | Composition pharmaceutique comprenant un betabloquant, un inhibiteur de l'enzyme de conversion et un antihypertenseur ou un ains |